Strategic Global Advisors LLC Grows Holdings in Astrazeneca Plc $AZN

Strategic Global Advisors LLC grew its holdings in Astrazeneca Plc (NYSE:AZN) by 205.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,106 shares of the company’s stock after purchasing an additional 6,796 shares during the period. Strategic Global Advisors LLC’s holdings in Astrazeneca were worth $1,774,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Brighton Jones LLC grew its position in shares of Astrazeneca by 93.2% during the 4th quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock worth $379,000 after buying an additional 2,789 shares in the last quarter. AQR Capital Management LLC grew its position in shares of Astrazeneca by 45.3% during the 1st quarter. AQR Capital Management LLC now owns 37,501 shares of the company’s stock worth $2,756,000 after buying an additional 11,690 shares in the last quarter. Amundi grew its position in shares of Astrazeneca by 54.4% during the 2nd quarter. Amundi now owns 10,274 shares of the company’s stock worth $731,000 after buying an additional 3,618 shares in the last quarter. Jump Financial LLC grew its position in shares of Astrazeneca by 898.4% during the 2nd quarter. Jump Financial LLC now owns 33,478 shares of the company’s stock worth $2,339,000 after buying an additional 30,125 shares in the last quarter. Finally, Daiwa Securities Group Inc. grew its position in shares of Astrazeneca by 1.2% during the 2nd quarter. Daiwa Securities Group Inc. now owns 46,642 shares of the company’s stock worth $3,259,000 after buying an additional 559 shares in the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on AZN shares. UBS Group reissued a “buy” rating on shares of Astrazeneca in a research report on Friday, April 10th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Tuesday, June 9th. TD Cowen reissued a “buy” rating on shares of Astrazeneca in a report on Wednesday, March 18th. Wall Street Zen upgraded Astrazeneca from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of Astrazeneca in a research report on Monday, June 8th. Twelve research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $205.33.

Astrazeneca Stock Up 0.0%

Astrazeneca stock opened at $178.79 on Monday. The stock has a market capitalization of $277.28 billion, a PE ratio of 26.85, a price-to-earnings-growth ratio of 1.55 and a beta of 0.25. Astrazeneca Plc has a 12 month low of $137.23 and a 12 month high of $212.71. The business has a 50 day simple moving average of $189.26 and a 200-day simple moving average of $186.07. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71.

Astrazeneca (NYSE:AZN) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. The business had revenue of $15.29 billion during the quarter, compared to analysts’ expectations of $14.93 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%. On average, analysts anticipate that Astrazeneca Plc will post 9.39 EPS for the current fiscal year.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.